Ispronicline meets Phase II endpoints

Targacept's ispronicline ( TC-1734, AZD3480) meet the three primary endpoints in a Phase II trial to treat age-associated memory impairment. On an intent to treat basis, those receiving 50 mg of ispronicline at 16 weeks showed a statistically significant change from baseline vs. placebo in the power of attention (p=0.014) and episodic memory (p=0.029) portions of a cognitive test battery, and in improvement in composite score of subject global impression (p=0.015). ...